3. About the Pathology Clinical Committee

The Pathology Clinical Committee (the Committee) was established in 2016 to make recommendations to the MBS Review Taskforce on the review of MBS items within its remit, based on rapid evidence review and clinical expertise.

3.1 Pathology Clinical Committee members

It is noted that the majority of the Committee members share a common conflict of interest in reviewing items that are a source of revenue for them (i.e. Committee members claim the items under review). This conflict is inherent in a clinician-led process, and having been acknowledged by the Committee and the Taskforce, it was agreed that this should not prevent a clinician from participating in the review.

Table 1: Pathology Clinical Committee Members
Name Position/organisation Declared
conflict of interest
Associate Professor
Peter Stewart
Royal Prince Alfred Hospital (Public) None
Professor Rita Horvath South Eastern Area Laboratory Services (Public) None
Dr Debra Norris QML Pathology (Primary) None
Dr Michael Harrison Sullivan Nicolaides Pathology (Sonic) None
Associate Professor Ken Sikaris Melbourne Pathology (Sonic) None
Dr Melody Caramins Specialist Diagnostic Services (Primary) None
Dr John Rowell Royal Brisbane & Women's Hospital None
Professor Dominic Mallon PathWest None
Dr Peter Roberts Ryde Hospital (AESM) None
Associate Professor Anthony Landgren Australian Clinical Labs None
Associate Professor Mary-Jo Waters St Vincent's Pathology (CHA) None
Professor Richard Maclsaac St Vincent's Hospital None
Dr Emil Djakic General practitioner None
Dr Bev Rowbotham MBS Taskforce None
Dr Jill Thistlethwaite General practitioner None
Dr Gary Lum Department of Health Medical Advisor None
Ms Valerie Hanrahan MBS Review Representative Consumer
Consumers Health Forum
None
Dr Robyn Lindner National Prescribing Service None
Professor Hans Schneider Director of Pathology, Alfred Pathology Service (Melbourne); Adjunct Clinical Professor, Central Clinical School, Monash University; President, Public Pathology Australia None
Associate Professor Adrienne Morey ACT Pathology (Public Sector): formerly SydPath, St Vincent’s (Catholic) None

3.2 Chemical Working Group

The Chemical Working Group is one of six clinical Working Groups that have been established to support the work of the Pathology Clinical Committee. It was established to review chemical pathology items, and make recommendations to the Pathology Clinical Committee based on rapid evidence review and clinical expertise. Their recommendations were endorsed by the Pathology Clinical Committee to go out for public comment before MBS Taskforce consideration.

The Chemical Working Group consists of nine members, whose names, positions/organisations and declared conflicts of interest are listed in Table 2 below. The following members were involved in the Chemical Working Group and have since resigned from the working group. Dr Nimalie Perera was involved from June to August 2016, Dr Glenn Edwards was involved from June to November 2016 and Dr Simon Morgan from October to November 2016. These members resigned before finalisation of the report.

Table 2: Chemical Working Group Members

Name Position/organisation Declared conflict of interest
Professor Hans Schneider (Chair) Director of Pathology, Alfred Pathology Service (Melbourne);
Adjunct Clinical Professor, Central Clinical School, Monash University;
President, Public Pathology Australia
Is the main biller of the tests at the Alfred, 100% of the proceeds are donated to the public hospital.
Dr Lawrie Bott Pathologist, Sonic Healthcare, Hobart Provider of MBS-funded services reviewed by this Committee.
Dr David Deam Chemical Pathologist, Australian Clinical Labs Provider of MBS-funded services reviewed by this Committee.
Dr Alan McNeil Chemical Pathologist, Dorevitch Pathology, Melbourne Nil
Dr Trina Gregory Clinical Director, Watson General Practice, ACT Requester of pathology
Ms Helen Maxwell-Wright MBS Review Representative Consumer
Director, Maxwell-Wright Associates
Nil

3.3 Conflicts of interest

All members of the Taskforce, Clinical Committees and Working Groups are asked to declare any conflicts of interest at the start of their involvement and reminded to update their declarations periodically.